64 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이민형-
dc.date.accessioned2018-03-22T05:27:00Z-
dc.date.available2018-03-22T05:27:00Z-
dc.date.issued2014-03-
dc.identifier.citationMolecular pharmaceutics,v.11,no.3 2014년, pp.938 - 950en_US
dc.identifier.issn1543-8384-
dc.identifier.urihttps://pubs.acs.org/doi/abs/10.1021/mp4006003-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/50494-
dc.description.abstractGene therapy has been considered a promising approach for glioblastoma therapy. To avoid side effects and increase the specificity of gene expression, gene expression should be tightly regulated. In this study, glioma and hypoxia dual-specific plasmids (pEpo-NI2-SV-Luc and pEpo-NI2-SV-HSVtk) were developed by combining the erythropoietin (Epo) enhancer and nestin intron 2 (NI2). In the in vitro studies, pEpo-NI2-SV-Luc showed higher gene expression under hypoxia than normoxia in a glioblastoma-specific manner. The MTT and caspase assays demonstrated that pEpo-NI2-SV-HSVtk specifically induced caspase activity and cell death in hypoxic glioblastoma cells. For in vivo evaluation, subcutaneous and intracranial glioblastoma models were established. Dexamethasone-conjugated-polyethylenimine (PEI-Dexa) was used as a gene carrier, since PEI-Dexa efficiently delivers plasmid to glioblastoma cells and also has an antitumor effect due to the effect of dexamethasone. In the in vivo study in the subcutaneous and intracranial glioblastoma models, the tumor size was reduced more effectively in the pEpo-NI2-SV-HSVtk group than in the control and pSV-HSVtk groups. In addition, higher levels of HSVtk gene expression and TUNEL-positive cells were observed in the pEpo-NI2-SV-HSVtk group compared with the control and pSV-HSVtk groups, suggesting that pEpo-NI2-SV-HSVtk increased the therapeutic efficacy in hypoxic glioblastoma. Therefore, pEpo-NI2-SV-HSVtk/PEI-Dexa complex may be useful for glioblastoma-specific gene therapy.en_US
dc.description.sponsorshipThis work was financially supported by the grants from the National Research Foundation of Korea, funded by the Ministry of Science, ICT and Future Planning (2013K000257 and 2013059236).en_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.subjectgene regulationen_US
dc.subjectgene therapyen_US
dc.subjectglioblastomaen_US
dc.subjecthypoxiaen_US
dc.subjectsuicide geneen_US
dc.titleDelivery of Hypoxia and Glioma Dual-Specific Suicide Gene Using Dexamethasone Conjugated Polyethylenimine for Glioblastoma-Specific Gene Therapyen_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume11-
dc.identifier.doi10.1021/mp4006003-
dc.relation.page938-950-
dc.relation.journalMOLECULAR PHARMACEUTICS-
dc.contributor.googleauthorKim, Hyun-Ah-
dc.contributor.googleauthorPark, Jin-Hyeong-
dc.contributor.googleauthorYi, Na-
dc.contributor.googleauthorLee, Min-hyung-
dc.relation.code2014036240-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidminhyung-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE